Was the solution inside you all along? For the first time, the U.S. Food and Drug Administration has approved a cell-based gene therapy. Called Kymriah, it can now be used to treat acute lymphoblastic leukemia, America’s most common childhood cancer, for patients 25 and younger. It uses a procedure called CAR-T, in which doctors remove a patient’s T-cells, modify them to attack cancerous cells, and return them to the bloodstream. If “living drugs” work, they could transform the fight against disease, and hopefully reduce Kymriah’s $475,000 cost.